- Home
- WDH vs FATE Comparison
WDH vs FATE Comparison
Compare WDH & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDH
- FATE
- Stock Information
- Founded
- WDH 2016
- FATE 2007
- Country
- WDH China
- FATE United States
- Employees
- WDH N/A
- FATE N/A
- Industry
- WDH Specialty Insurers
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WDH Finance
- FATE Health Care
- Exchange
- WDH Nasdaq
- FATE Nasdaq
- Market Cap
- WDH 420.6M
- FATE 406.5M
- IPO Year
- WDH 2021
- FATE 2013
- Fundamental
- Price
- WDH $1.19
- FATE $1.68
- Analyst Decision
- WDH
- FATE Hold
- Analyst Count
- WDH 0
- FATE 10
- Target Price
- WDH N/A
- FATE $6.75
- AVG Volume (30 Days)
- WDH 142.9K
- FATE 4.4M
- Earning Date
- WDH 12-11-2024
- FATE 11-12-2024
- Dividend Yield
- WDH 4.44%
- FATE N/A
- EPS Growth
- WDH 31.72
- FATE N/A
- EPS
- WDH 0.11
- FATE N/A
- Revenue
- WDH $391,241,143.00
- FATE $13,447,000.00
- Revenue This Year
- WDH N/A
- FATE N/A
- Revenue Next Year
- WDH $8.36
- FATE N/A
- P/E Ratio
- WDH $9.48
- FATE N/A
- Revenue Growth
- WDH 3.53
- FATE N/A
- 52 Week Low
- WDH $0.94
- FATE $1.59
- 52 Week High
- WDH $1.53
- FATE $8.83
- Technical
- Relative Strength Index (RSI)
- WDH 58.22
- FATE 35.65
- Support Level
- WDH $1.08
- FATE $1.59
- Resistance Level
- WDH $1.24
- FATE $2.07
- Average True Range (ATR)
- WDH 0.06
- FATE 0.25
- MACD
- WDH 0.00
- FATE -0.08
- Stochastic Oscillator
- WDH 68.75
- FATE 6.47
About WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. It is a third-party insurance platform in China in terms of life and health insurance.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.